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ABSTRACT 
The development of RNAi-based genetic tools to silence MKP3 expression in a 
cell-specific manner 
Sayani Patra 
Dr. Ole Mortensen 
 
Drug addiction is believed to occur, in part, as a result of maladaptive 
changes in dopaminergic pathways. The extracellular signal-regulated kinase 1/2 
(ERK1/2) mitogen-activated protein (MAP) kinase signaling pathway is implicated 
in altering dopaminergic signaling. Previous work demonstrated that MAP kinase 
phosphatase-3 (MKP3), a negative regulator of the ERK1/2 pathway, modulates 
dopamine release by altering dopamine transporter surface expression and 
voltage-gated calcium channel expression. Most pharmacological and genetic 
tools lack the ability to modulate intracellular signaling pathways in vivo in a cell-
specific manner. Development of such cell-specific genetic tools can be used to 
study the role of long term plasticity changes in pathologies such as drug addiction. 
The goal of this project was to develop a cell-specific RNAi-based genetic 
tool to target and alter MKP3 expression in vivo. Cre recombinase-dependent 
expression of a microRNA-30-based shRNA vector is used to silence MKP3 
expression. Cre recombinase reorients a transcript of interest and only expresses 
it in cells containing Cre. An inverted shRNA construct is flanked by incompatible 
lox P sites, and Cre recombinase reverses the orientation of the construct to 
enable cell-specific MKP3 silencing in vivo. 
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This study tested 4 shRNAs that target different regions of the MKP3 
reading frame to determine which shRNA induces the most effective MKP3 
silencing in vitro. shRNAs were first cloned into DNA vectors that contain 
incompatible lox P sites and a promoter needed for expression of the shRNA. 
Proper cloning of shRNAs was verified with agarose gel analysis and DNA 
sequencing. After optimizing transfection conditions, in vitro studies showed that 
only 2 shRNAs significantly silenced MKP3 expression; only 1 of those shRNAs 
showed good red fluorescent protein (RFP) expression. Since these shRNAs were 
oriented in the forward direction, adding Cre to the shRNA samples reversed their 
orientation and prevented their expression, which was observed through reduced 
RFP expression and reversal of the MKP3 silencing effects seen without Cre. Thus 
both MKP3 silencing and RFP expression are Cre dependent. Future in vivo 
studies will assess MKP3’s role in cocaine addiction by using the most effective 
shRNA to silence MKP3 expression only in dopaminergic neurons that contain Cre.  
xi 
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INTRODUCTION 
 
Project Significance 
The RNA interference (RNAi) based genetic tool being developed in this project 
can be used widely to study many different molecular areas of interest with a 
degree of specificity not available using other currently available methods. Our lab 
seeks to develop this tool in order to study the underlying molecular mechanisms 
of cocaine addiction.  
In general, drug use, drug abuse, and drug addiction are major problems in society. 
Cocaine, a psychostimulant, is one of the most addictive drugs, causing cocaine 
users to become highly dependent on the drug. Addiction occurs when users 
compulsively use the drug despite knowing the negative consequences of drug 
use (1). Cocaine addiction contributes to a significant number of deaths each year 
due to cocaine overdose (2). Overall, the treatment of cocaine addiction is a critical 
unmet medical need since there are currently no Food and Drug Administration 
approved treatments available for cocaine overdose and addiction (3). 
Cocaine users make up a significantly large portion of drug addicts, and cocaine 
addiction continues to be a large burden to society as the number of new addicts 
continues to increase, especially among young adults (4). Therefore, much effort 
is being made to better understand cocaine addiction so that possible treatments 
can eventually be developed. Scientific research in this field primarily focuses on 
understanding the underlying molecular mechanisms of cocaine addiction, and 
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how these mechanisms lead to long lasting maladaptive changes in the brain that 
translate into the formation of addictive behaviors. 
The uniqueness of the RNAi-based genetic tool being developed in this project is 
the cell specificity that can be achieved with this tool. Such a genetic tool can help 
study these underlying molecular mechanisms of cocaine addiction in a cell-
specific and circuit-specific manner, meaning that this tool can be used in vivo to 
modulate the expression of a protein in a particular region or cell type without 
affecting its expression elsewhere in the animal. The ability to target and modulate 
protein expression in a specific cell type or region is crucial to determine very 
specific molecular mechanisms in certain cell types or regions, and how these 
molecular mechanisms can compare or contrast to molecular mechanisms in other 
cell types or regions. Thus, this tool can not only help uncover the role and 
importance of specific proteins in the molecular mechanisms underlying cocaine 
addiction (as well as any other molecular area of interest), but this tool can also 
help identify new molecular targets in disease areas that may eventually lead to 
the future development of new treatment approaches. 
 
Cocaine and Its Mechanism of Action 
Cocaine exerts its effect in the central nervous system (CNS) by acting on the 
mesolimbic dopamine pathway, which is one of the most important reward 
pathways of the brain. Reward pathways in the brain are important for processing 
rewarding stimuli such as food or drugs. These pathways regulate our ability to 
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feel pleasure from rewarding stimuli, and motivate us to repeat behaviors that 
restore the pleasurable feeling in the brain, such as eating food or taking drugs (1). 
Rewarding stimuli activate dopaminergic neurons in the ventral tegmental area 
(VTA), which sends projections to various regions of the brain including the 
nucleus accumbens, often referred to as the brain’s pleasure center. Activation of 
these dopaminergic neurons causes dopamine release in these brain regions, 
which leads to the perceived feeling of pleasure. It is important to note that with 
repeated exposure to cocaine, this pathway remains activated even in the absence 
of cocaine, which leads to feelings of craving and makes the body become 
dependent on the drug to maintain the rewarding feeling. Thus, cocaine’s effects 
are both rewarding as well as reinforcing (1). 
Cocaine disrupts dopamine neurotransmission and elevates extracellular levels of 
dopamine at the synapse of dopaminergic neurons by blocking the presynaptic 
dopamine transporter (DAT) that usually mediates reuptake of the extracellular 
dopamine back into the presynaptic neuron (shown in Figure 1) (5). Cocaine’s 
rewarding and addictive effects are produced from elevated levels of dopamine at 
the synapse, which leads to increased binding of dopamine to dopamine receptors 
on postsynaptic dopaminergic neurons, thereby hyperactivating these 
postsynaptic neurons and resulting in an intense feeling of euphoria and pleasure 
(1). 
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Figure 1. Cocaine’s effect on dopaminergic signaling in the CNS. Cocaine disrupts 
normal dopamine neurotransmission by blocking DAT and increasing dopamine 
levels at the synapse, which leads to hyperactivation of postsynaptic dopaminergic 
neurons and the production of a euphoric feeling (5). 
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Although the addictive effects of cocaine have been found to be primarily due to 
its effect on dopaminergic neurons, cocaine also blocks the serotonin and 
norepinephrine transporters and therefore also elevates serotonin and 
norepinephrine levels at synapses (1).  
Chronic use of cocaine leads to long lasting adaptive changes in the brain (6). Drug 
addiction is believed to result from repeated drug exposure that leads to long 
lasting maladaptive changes in dopaminergic signaling pathways. However, it is 
unclear what types of molecular mechanisms cause these adaptive changes that 
ultimately lead to the formation of addiction. It is important to study these adaptive 
changes in order to better understand how cocaine addiction forms. Understanding 
these specific molecular mechanisms can help identify possible targets for the 
treatment of cocaine addiction. 
 
The ERK1/2 Signaling Pathway and its Role in Addiction 
Shown in Figure 2 is the extracellular signal-regulated kinase 1/2 (ERK1/2) 
mitogen-activated protein (MAP) kinase signaling pathway (7), which is activated 
by cocaine and is believed to undergo adaptive changes as a result of repeated 
exposure to cocaine (6).  
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Figure 2. The ERK1/2 MAP kinase signaling pathway. An extracellular growth 
factor binds to a growth receptor on the cell membrane surface, which initiates a 
cascade of signaling events in the cytoplasm that ultimately leads to the 
phosphorylation of ERK, which can then translocate into the nucleus to activate 
genes that will promote cell growth and differentiation. MKP3 inactivates ERK (7). 
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It has been demonstrated in several studies that the ERK1/2 MAP kinase signaling 
pathway alters dopaminergic signaling (8). ERK1/2 signaling has been seen to 
affect cocaine-associated addictive behavior such as locomotor sensitization and 
conditioned place preference (9). It has also been observed that repeated 
exposure to cocaine not only leads to increased phosphorylation of ERK1/2 in the 
VTA, but also leads to long term adaptations in synaptic plasticity, suggesting that 
the ERK1/2 signaling pathway may be important in carrying out the long term 
effects of drug abuse (6). However, it is not known through which cell types (i.e. 
neurons) these effects of ERK1/2 are mediated. The development of the cell-
specific genetic tool in this project can help address that question. 
Our lab is interested in studying a key phosphatase and negative regulator in this 
pathway known as MAP kinase phosphatase 3 (MKP3) (10). In the ERK1/2 
signaling pathway, MKP3 functions to dephosphorylate the activated ERK1/2, 
thereby inactivating it (shown in Figure 3).  
 
 
Figure 3. The inactivation of ERK by MKP3. In the ERK1/2 signaling pathway, MEK 
phosphorylates ERK to activate it. ERK is dephosphorylated/ inactivated by MKP3. 
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Previous work in the lab has used genetic complementation screening in Xenopus 
oocytes and has identified MKP3 as a regulator of dopamine transporter trafficking 
(11). This work has shown that MKP3 modulates dopaminergic neurochemistry, 
such as altering DAT surface expression by inhibiting its internalization via protein 
kinase C and thereby enhancing the activity of DAT (11). Previous work in the lab 
has also shown that MKP3 decreases dopamine release by downregulating L-type 
voltage-gated calcium channel expression of the Cav1.2 alpha subunit (12). These 
observed effects are essentially the opposite effects of cocaine, which elevates 
dopamine levels at the synapse instead of decreasing its release. This suggests 
that MKP3 may be playing a key role against the effects of cocaine on 
dopaminergic signaling. 
It has also been seen in other studies that the expression of other phosphatases 
such as MKP1 is increased in the VTA by chronic exposure to addictive drugs such 
as amphetamine, and that this increased phosphatase expression is mediated by 
upregulation of the Cav1.2 alpha subunit of L-type calcium channels (13). 
However, all of this work has been conducted in vitro and it is largely unknown how 
all of these observations and adaptations are affecting and modulating addictive 
behavior in vivo. Therefore, this project seeks to modulate MKP3 expression in 
vivo in dopaminergic neurons in order to better understand its role in cocaine 
addiction. 
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The Need for an in vivo Genetic Tool 
One of the more significant current challenges in this field is that genetic and 
pharmacological tools lack the ability to specifically modulate intracellular signaling 
pathways in vivo in a cell-specific or circuit-specific manner. For example, our lab 
wants to study MKP3 silencing in just dopaminergic neurons without affecting its 
expression in other cell types, since silencing MKP3 expression in the entire animal 
would severely affect its normal functioning and development. Therefore, to 
address this challenge, this project seeks to develop an in vivo genetic tool that 
can modulate intracellular signaling pathways in a cell-specific manner, and by 
doing so, it enables the ability to study long term plasticity changes in the brain for 
a variety of pathologies, including drug addiction, psychiatric disorders, as well as 
neurodegenerative diseases.  
As mentioned before, such a genetic tool can be used to modulate and study any 
specific protein of interest. However, for the purposes of this study, this genetic 
tool will be developed to specifically silence MKP3 expression in only dopaminergic 
neurons by using transgenic rats that express Cre recombinase exclusively in 
tyrosine hydroxylase (TH) containing cells, which are indicative of dopaminergic 
neurons. Other transgenic Cre animals are also available, especially transgenic 
mice that express Cre in other cell types (14). Therefore, the Cre-based genetic 
tool being developed in this project can be used widely in other studies that utilize 
transgenic Cre animals (15). 
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The Development of an RNAi-Based Genetic Tool That Utilizes Cre Recombinase 
Cre recombinase technology allows for the modulation of a protein of interest in a 
cell-specific or circuit-specific manner (16). As an example, for MKP3 
overexpression exclusively in dopaminergic cells, the reverse direction (R) of the 
MKP3 transcript would need to be inserted in between incompatible Lox2272 and 
LoxP sites. In any cell that contains Cre recombinase (in this case, only 
dopaminergic cells), Cre will revert the orientation of the MKP3 transcript and 
cause it to be expressed since it would now be in the forward direction orientation. 
The genetic tool overexpressing MKP3 in dopaminergic neurons (AAV-FLEX-
MKP3-R vector) has already been developed, and a basic schematic of this tool is 
shown in Figure 4. 
 
 
Figure 4. Cre recombinase dependent overexpression of MKP3. Green fluorescent 
protein (GFP) and MKP3 constructs in their reverse direction (inactive) can be 
positioned inside lox P sites so that cells containing Cre can reorient the constructs 
to their forward direction, enabling cell-specific expression of the constructs. 
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This specific study will seek to silence MKP3 expression with a similar genetic tool. 
To silence MKP3 expression in dopaminergic neurons, a microRNA-30 (miR30)-
based short hairpin RNA (shRNA) vector will be used, as shown in Figure 5. 
miRNAs are endogenous noncoding RNAs that regulate post-transcriptional 
silencing of gene expression through the RNAi pathway (17). shRNA was used 
instead of short interfering RNA (siRNA) since gene silencing effects of shRNA are 
typically more potent and long lasting that siRNA (18), and lead to less off-target 
silencing effects than siRNA (19). The miR30-based shRNA vector will contain 
flanking sequences (5’miR30 and 3’miR30) of microRNA-30 (17). This specific 
vector design was used since these microRNA-30 flanking sequences are known 
to significantly mediate RNAi effects by increasing the processing of the shRNA by 
RNAi proteins such as Drosha and Dicer (20).  
 
 
Figure 5. Cre dependent MKP3 silencing using reverse direction shRNA. Red 
fluorescent protein (RFP) and shRNA constructs in their reverse direction can be 
positioned inside lox P sites so that cells containing Cre can reorient the constructs 
to their forward direction, enabling cell-specific expression of the constructs. 
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An shRNA targeting a specific sequence within the MKP3 gene reading frame will 
be inserted in its reverse direction in between the 5’miR30 and the 3’miR30 
sequences of the miR30-based vector, which will be flanked on both sides by 
incompatible Lox2272 and LoxP sites. A red fluorescent protein (RFP) sequence 
will also be inserted in its reverse direction right before the 5’miR30 and the shRNA 
sequences so that it can be verified by RFP expression if the shRNA is being 
successfully expressed or not. As discussed before in the MKP3 overexpression, 
Cre recombinase (only in dopaminergic neurons) will flip the orientation of both the 
RFP sequence and the shRNA sequence, causing both of them to now be in the 
forward direction and therefore being expressed (21). The shRNA can then 
function to specifically silence MKP3 expression in dopaminergic neurons while 
leaving other cell types unaffected since other cells will not contain Cre 
recombinase and therefore the shRNA will still be in its reverse direction in these 
other cell types. 
For this project, the shRNA construct was first cloned into a flip-excision (FLEX) 
DNA vector which contains the incompatible Lox2272 and LoxP sites. For in vitro 
studies, this shRNA was then further cloned into a pcDNA3.1 vector that contains 
a cytomegalovirus (CMV) forward promoter that will allow expression of the 
shRNA. However, for future in vivo studies, the shRNA will be engineered into an 
adeno-associated viral (AAV) vector with a different promoter. 
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Overall Project Goals and Specific Aims 
The overall long-term goal for this entire project (extending further than this thesis) 
is to study MKP3’s role in cocaine addiction by modulating its expression through 
Cre-recombinase based genetic tools that will specifically target and alter MKP3 
expression only in dopaminergic neurons. This specific study or thesis seeks to 
develop an RNAi-based genetic tool that utilizes Cre-recombinase dependent 
expression of a miR30-based shRNA vector in order to silence MKP3 expression, 
with the hope that the foundation provided by this study will enable the use of this 
tool in future in vivo studies to study cocaine addiction in the absence of MKP3 in 
dopaminergic cells. 
In this specific study, 4 distinct shRNAs targeting different regions of the MKP3 
reading frame will be used in their forward direction to silence MKP3 expression, 
as shown in Figure 6. The shRNA constructs were designed based on algorithms 
provided by Cold Spring Harbor Laboratory at RNAi Central, which were developed 
by Dr. Gregory Hannon (17). 
 
 
Figure 6. shRNAs target different regions of the MKP3 reading frame. Targeting 
different regions of the MKP3 gene will allow for selection of the shRNA that 
induces the most effective silencing of MKP3. 
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It is important to note that the shRNAs used in this specific part of the study will be 
engineered in the forward direction (as shown in Figure 7), as opposed to the 
eventual shRNA that will be engineered in its reverse direction. The purpose of this 
differential design is to first establish in vitro which one of the shRNAs is most 
effective at inducing MKP3 silencing before introducing Cre into the design. Thus 
with the forward direction shRNA, the addition of Cre in vitro will actually cause the 
shRNA to become reversed and therefore no longer able to silence MKP3 in vitro, 
as shown in Figure 7. 
 
 
Figure 7. Cre’s effect on MKP3 silencing using forward direction shRNA. RFP and 
shRNA constructs in their forward direction can be actively expressed without Cre. 
However, since they are positioned inside lox P sites, the presence of Cre reorients 
the constructs to their reverse direction, which prevents expression of the shRNA. 
 
Therefore, the main purpose of this thesis is to study the MKP3 silencing effects 
of the 4 shRNAs in vitro and determine which shRNA is the most effective at 
silencing MKP3 expression, since this selected shRNA will be engineered in the 
AAV vector to induce MKP3 silencing in vivo. As mentioned before, to do this the 
shRNAs will first have to be cloned into a FLEX DNA vector containing the 
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incompatible Lox2272 and LoxP sites, and then further cloned into the pcDNA3.1 
vector in order to be expressed by the CMV forward promoter. Cre-dependent 
silencing of MKP3 expression in vitro will also be explored in this study, i.e. how 
the presence of Cre affects MKP3 silencing induced by the shRNAs. 
 
Previous Studies Relevant to This Project 
As mentioned before, the genetic tool overexpressing MKP3 in dopaminergic 
neurons using an AAV vector (AAV-FLEX-MKP3-R) has already been developed 
by Dr. Ole Mortensen’s lab and is currently being studied for its effects on cocaine 
addiction in transgenic rats that express Cre recombinase in TH containing cells 
(dopaminergic neurons). Since the specificity of both the AAV-FLEX-MKP3-R 
vector and the MKP3 silencing tool will be the same (i.e. specific overexpression 
or silencing of MKP3 only in dopaminergic neurons), it is important to consider the 
specificity that the AAV-FLEX-MKP3-R vector has shown in these transgenic rats. 
Figure 8 shows the cell-specific overexpression of MKP3 that was induced by the 
AAV-FLEX-MKP3-R vector (Mortensen, OV Unpublished). The leftmost panel 
shows cells containing TH (in red), which are indicative of dopaminergic neurons. 
The middle panel shows the cells overexpressing MKP3 (in green), which was 
induced by the AAV-FLEX-MKP3-R vector. The rightmost panel shows the co-
localization of these two expressions, which indicates that the AAV-FLEX-MKP3-
R vector induced MKP3 overexpression only in dopaminergic neurons since Cre 
recombinase was only expressed in dopaminergic neurons. 
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Figure 8. Cell-specific overexpression of MKP3 in vivo using an AAV vector. Co-
localization of TH containing cells (red) and cells with MKP3 overexpression 
(green) indicates that the AAV vector induced cell-specific overexpression of 
MKP3 in TH containing cells (dopaminergic neurons). 
 
It is also worth considering some of the behavioral effects that the AAV-FLEX-
MKP3-R vector has shown. Figure 9 shows how the overexpression of MKP3 
affects cocaine-induced locomotion (Mortensen, OV Unpublished). Compared to 
control rats (injected with a control AAV vector), rats that had overexpression of 
MKP3 (induced by the AAV-FLEX-MKP3-R vector) displayed less locomotive 
activity after receiving cocaine, which suggests that MKP3 may play a protective 
role against mediating the locomotor effects usually seen with cocaine 
administration.  
17 
 
 
 
Figure 9. The effect of MKP3 overexpression on cocaine-induced locomotion. 
MKP3 overexpression in dopaminergic neurons using an AAV vector reduced 
cocaine-induced locomotion compared to rats that received a control AAV vector.  
18 
 
MATERIALS AND METHODS 
 
Materials 
The following items were purchased from New England Biolabs (Ipswich, MA): 
BspQ1 restriction enzyme, BamHI-HF restriction enzyme, XbaI restriction enzyme, 
10X 3.1 NE buffer, Quick Ligase, 2X quick ligase reaction buffer, 10X CutSmart 
buffer, antartic phosphatase, E. coli competent bacteria, and SOC medium 
(abbreviated for super optimal broth with catabolic repression). 
Items purchased from Invitrogen (Carlsbad, CA) include the XCell SureLock Mini-
Cell Western Blot apparatus, 10X BlueJuice gel loading dye, agarose, 50X TAE 
buffer (containing Tris base, acetic acid and ethylenediaminetetraacetic acid 
[EDTA] ), 10 mg/mL ethidium bromide, customized single-stranded shRNA oligos, 
FLEX-SEQ forward primer, FLEX-R reverse primer, the pcDNA3.1 vector, and 
TrackIt 1Kb Plus DNA Ladder. 
Purchases from Corning Cellgro (Manassas, VA) include 1X DMEM (Dulbecco’s 
Modification of Eagle’s Medium) with 4.5 g/L glucose, L-glutamine and sodium 
pyruvate, Fetal Bovine Serum, 100X Penicillin Streptomycin solution, 10X 
Dulbecco’s phosphate buffered saline (PBS) without calcium & magnesium, 0.05% 
Trypsin with 0.53mM EDTA and 1X sodium bicarbonate. 
Items from Thermo Fisher Scientific (Waltham, MA) include Luria Broth, 12-well 
plates, methanol, NuPAGE 4X lithium dodecyl sulfate (LDS) sample buffer, 15-well 
NuPAGE Novex 4-12% Bis-Tris Gels, 20X NuPAGE MOPS SDS Running Buffer, 
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20X NuPAGE Transfer Buffer, mouse Myc epitope-tagged MKP3 antibody, and 
mouse RFP tag antibody. 
From Cell Signaling Technology (Danvers, MA), the prestained broad range 
protein marker, rabbit actin antibody, Anti-Mouse IgG DyLight 680 Conjugate, and 
Anti-Rabbit IgG DyLight 800 4X PEG Conjugate were purchased. 
The QIAquick Gel Extraction Kit, QIAprep Spin Miniprep Kit, and Plasmid Plus Midi 
Kit were purchased from Qiagen (Valencia, CA). Kanamycin and Carbenicillin 
antibiotics were purchased from Sigma-Aldrich (St. Louis, MO). Myc-tagged MKP3 
DNA was purchased from Origene (Rockville, MD). Poly-D-Lysine (PDL) was 
purchased from Santa Cruz Biotechnology (Dallas, TX). The LipoJet in vitro 
Transfection Kit was purchased from SignaGen Laboratories (Rockville, MD). 
Dithiothreitol reducing agent was purchased from Bio-Rad Laboratories (Hercules, 
CA). Immobilon-FL polyvinylidene fluoride (PVDF) membrane and Blotting Filter 
Paper were purchased from EMD Millipore (Billerica, MA). Odyssey blocking buffer 
was purchased from LI-COR Biosciences (Lincoln, NE). 
The human embryonic kidney (HEK293) cell line was obtained from the American 
Type Culture Collection. DNA concentrations for samples were measured using 
the Nanodrop 1000 apparatus (Nanodrop Technologies, Wilmington, DE). DNA 
samples were sent for sequencing at Genewiz (South Plainfield, NJ). Western Blot 
data was analyzed using the LI-COR Image Studio software, version 4.0.21 (LI-
COR Biosciences, Lincoln, NE). The GraphPad Prism version 5 for PC (GraphPad 
Software, La Jolla, CA) was used to further analyze data as well as create graphs. 
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Molecular Cloning of shRNA Constructs into FLEX-RFP-shRNA DNA Vector 
 
Figure 10 shows a schematic of how the shRNA constructs were cloned into the 
FLEX-RFP-shRNA vector, the methods for which will be described in this section. 
 
 
Figure 10. Molecular cloning of shRNA into FLEX-RFP-shRNA vector. The FLEX-
RFP-shRNA vector was digested with BspQ1 restriction enzyme, isolated from an 
agarose gel, and then ligated to the shRNA constructs. 
 
Digestion of the FLEX-RFP-shRNA DNA Vector 
The pJ241-FLEX DNA vector (22) was used to construct the FLEX-RFP-shRNA 
vector (20), the latter of which was used in this study. The FLEX-RFP-shRNA 
vector (10 µg DNA [10 µL of 1 µg/µL DNA]) was digested with BspQ1 restriction 
enzyme (2 µL) in a 40 µL reaction with water (24 µL) and 10X 3.1 NE buffer (4 µL) 
for 1 hour at 50°C.  
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Isolation of FLEX DNA from an Agarose Gel 
The digested FLEX vector (40 µL) was then mixed with 5 µL 10X BlueJuice gel 
loading dye and run on a 1% agarose gel (1 g agarose in 100 mL 50X TAE buffer 
with 5 µL of 10 mg/mL ethidium bromide for 1 hour at 130 V. The larger DNA 
fragment was isolated from the gel using a razor blade under UV light. DNA was 
isolated from the gel fragment using the QIAquick Gel Extraction Kit. The gel 
fragment was dissolved using QG buffer (900 µL) for 10 minutes at 50°C. 
Isopropanol (300 µL) was added to the dissolved gel mixture, which was then 
filtered in a spin column under vacuum and washed with PE buffer (750 µL) and 
brief centrifugation (1 minute at 13000 rpm). DNA was eluted from the mixture 
using EB buffer (30 µL) and brief centrifugation (1 minute at 13000 rpm). This FLEX 
DNA fragment was later used for ligation with shRNA to form the 4 FLEX-shRNA 
constructs. 
 
Annealing shRNA Oligos 
Customized single-stranded shRNA oligos were reconstituted with TE buffer for a 
final concentration of 1 µg/µL. Four shRNA constructs will be used in this study: 
shRNA1-1254, shRNA2-1096, shRNA3-1373, and shRNA4-1337. For each of the 
4 shRNAs, the forward direction shRNA oligo (2 µL) was annealed to the reverse 
direction shRNA oligo (2 µL) with annealing buffer (46 µL) and incubation at 90°C 
for 5 minutes. The annealed shRNAs were slowly cooled at room temperature for 
approximately 45 minutes prior to ligation with the earlier isolated FLEX DNA 
fragment.  
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Ligation of shRNA Constructs to the FLEX DNA Vector 
Each of the 4 shRNAs (1 µL) were ligated to the isolated FLEX DNA fragment (1 
µL) using quick ligase (1 µL) in a 21 µL reaction with water (8 µL) and 2X quick 
ligase reaction buffer (10 µL) for 5 minutes at room temperature. This led to the 
formation of 4 FLEX-shRNA-MKP3 constructs. 
 
Transformation and Plating of Competent Bacteria with FLEX-shRNA-MKP3 
Constructs 
The ligated FLEX-shRNA-MKP3 constructs were then transformed (inserted) into 
competent bacteria by incubating the FLEX-shRNA-MKP3 ligation mixtures (1 µL) 
with E. coli (12.5 µL) in ice for 30 minutes, then heat-shocked at 42°C for 30 
seconds and then again incubated in ice for 5 minutes, after which SOC medium 
(250 µL) was added to the mixtures and the cultures were shaken in a 37°C 
incubator for 1 hour. These cultures (150 µL) were then plated on agar plates with 
50 mg/mL Kanamycin antibiotic. Plates were incubated at 37°C overnight for the 
formation of bacterial colonies with the FLEX-shRNA-MKP3 DNA. 
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Miniprep DNA Extraction of FLEX-shRNA-MKP3 Constructs from Bacterial 
Colonies 
The FLEX-shRNA-MKP3 DNA was extracted from the bacterial colonies using the 
QIAprep Spin Miniprep Kit. Bacterial colonies were prepped 1 day prior to Miniprep 
by picking a bacterial colony from the respective FLEX-shRNA plate with a 
toothpick and growing the colony in Luria Broth (3 mL) and 50 mg/mL Kanamycin 
antibiotic (3 µL) by shaking the cultures in a 37°C incubator overnight. For each of 
the 4 Flex-shRNA plates, 3 bacterial colonies were grown for Miniprep.  
For the Miniprep procedure the next day, each bacterial culture (1.5 mL) was 
centrifuged at 13000 rpm for 3 minutes, upon which the supernatant was removed 
and the bacterial pellet was resuspended in Buffer P1 (250 µL). The cells in this 
mixture were then lysed using Buffer P2 (250 µL) and then neutralized using Buffer 
N3 (250 µL), after which the mixture was centrifuged at 13000 rpm for 10 minutes. 
The supernatant of this mixture was then transferred to a spin column under 
vacuum, to which binding Buffer PB (500 µL) and wash Buffer PE (750 µL) were 
added. The spin column was centrifuged at 13000 rpm for 1 minute to discard the 
remaining wash solution. To elute the DNA from the spin column, elution Buffer 
EB (50 µL) was added to the spin column placed in an Eppendorf tube. The spin 
column was incubated with the elution buffer for 1 minute and then centrifuged at 
13000 rpm for 1 minute to collect the FLEX-shRNA-MKP3 DNA solution in the 
Eppendorf tube. 
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Sequencing of FLEX-shRNA-MKP3 DNA Samples 
The 3 DNA samples for each of the 4 FLEX-shRNA-MKP3 constructs (12 DNA 
samples total) were sent for sequencing in order to verify proper incorporation of 
the shRNAs into the FLEX DNA vector. The samples sent for sequencing were 
prepared as follows. For each of the 12 DNA samples, 2 separate reactions (15 µL 
each) were prepared, containing that DNA (5 µL), water (9 µL), and either a FLEX-
SEQ forward primer (1 µL) or a FLEX-R reverse primer (1 µL), resulting in a total 
of 24 samples sent for sequencing from 12 DNA samples.  
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Molecular Cloning of FLEX-shRNA-MKP3 Constructs into the pcDNA3.1 Vector 
 
Figure 11 shows a schematic of how FLEX-shRNA-MKP3 constructs were cloned 
into the pcDNA vector, the methods for which will be described in this section. 
 
 
Figure 11. Molecular cloning of FLEX-shRNA-MKP3 into pcDNA vector. Both 
pcDNA and FLEX-shRNA-MKP3 constructs were digested with BamHI and XbaI 
restriction enzymes, isolated from an agarose gel, and then ligated to each other 
to form the final 4 pcDNA-FLEX-shRNA-MKP3 DNA samples. 
 
Digestion of the FLEX-shRNA-MKP3 Constructs and the pcDNA Vector 
The 4 FLEX-shRNA-MKP3 samples (10 µg or 20 µL) that were verified by 
sequence analysis were each digested overnight at 37°C with BamHI-HF (1 µL) 
and XbaI (1 µL) restriction enzymes in a 40 µL reaction with water (14 µL) and 10X 
CutSmart buffer (4 µL). The pcDNA3.1 vector (5 µL, 5428 base pairs) was also 
digested overnight at 37°C with the same restriction enzymes (1 µL of BamHI-HF 
and 1 µL of XbaI) in a 40 µL reaction with water (29 µL) and 10X CutSmart buffer 
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(4 µL). It is important to note that the FLEX-shRNA-MKP3-4-1337 sample was only 
digested with XbaI and not digested with BamHI-HF. 
 
Treatment of Digested FLEX-shRNA-MKP3 and pcDNA Samples 
The next day, the digested pcDNA sample underwent phosphatase treatment for 
1 hour at 37°C with 10X 3.1 NE buffer (5 µL) and antartic phosphatase (1 µL). 
Next, the phosphatase-treated pcDNA sample and the 4 digested FLEX-shRNA-
MKP3 samples underwent heat treatment for 20 minutes at 65°C to inactivate 
enzyme activity.  
 
Isolation of Digested FLEX-shRNA-MKP3 and pcDNA Samples from an Agarose 
Gel 
All 5 samples (46 µL of pcDNA sample and 40 µL of the 4 FLEX-shRNA-MKP3 
samples) were then mixed with 5 µL 10X BlueJuice gel loading dye and run on a 
1% agarose gel with 5 µL ethidium bromide for 1 hour at 130 V. For the pcDNA 
sample, the entire DNA fragment was isolated from the gel using a razor blade 
under UV light, while only the smaller DNA fragment was isolated for the 4 FLEX-
shRNA-MKP3 samples. DNA was isolated from the gel fragment using the 
QIAquick Gel Extraction Kit as described previously (for the molecular cloning of 
the shRNA constructs into the FLEX vector). These 5 isolated DNA samples were 
later used in several ligation reactions to form the 4 pcDNA-FLEX-shRNA-MKP3 
clones. 
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Ligation of FLEX-shRNA-MKP3 Constructs to the pcDNA Vector 
To form the 4 pcDNA-FLEX-shRNA-MKP3 clones, each of the 4 isolated FLEX-
shRNA-MKP3 samples (9 µL) were ligated to the isolated pcDNA sample (1 µL) 
using quick ligase (1 µL) in a 21 µL reaction with 2X quick ligase reaction buffer 
(10 µL) for 10 minutes at room temperature. The identities of the 4 clone samples 
are as follows: pcDNA-FLEX-shRNA-MKP3-1-1254, pcDNA-FLEX-shRNA-MKP3-
2-1096, pcDNA-FLEX-shRNA-MKP3-3-1373, and pcDNA-FLEX-shRNA-MKP3-4-
1337.  
 
Transformation and Plating of Competent Bacteria with pcDNA-FLEX-shRNA-
MKP3 Clones 
The ligated pcDNA-FLEX-shRNA-MKP3 samples were then transformed into 
competent bacteria as described previously (for the molecular cloning of the 
shRNA constructs into the FLEX vector). The one exception to the previously 
described bacterial transformation procedure is that bacterial cultures of these 
pcDNA-FLEX-shRNA-MKP3 samples were plated on agar plates with 50 mg/mL 
Carbenicillin antibiotic instead of Kanamycin antibiotic since these DNAs have 
different selection markers. 
 
Miniprep DNA Extraction of pcDNA-FLEX-shRNA-MKP3 Clones from Bacterial 
Colonies 
The pcDNA-FLEX-shRNA-MKP3 DNA was extracted from the bacterial colonies 
using the QIAprep Spin Miniprep Kit, as described previously (for the molecular 
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cloning of the shRNA constructs into the FLEX vector). The one exception to the 
previously described Miniprep DNA extraction procedure is that bacterial colonies 
containing pcDNA-FLEX-shRNA-MKP3 clones were grown in Luria Broth with 50 
mg/mL Carbenicillin antibiotic instead of Kanamycin antibiotic (since these DNAs 
have different selection markers). For each of the 4 pcDNA-FLEX-shRNA-MKP3 
plates, several bacterial colonies were grown for Miniprep, ranging from 4 to 10 
colonies per plate over the course of several repetitions of the same experiment. 
 
Verification of FLEX-shRNA-MKP3 Ligation to the pcDNA Vector using Agarose 
Gel Analysis 
All Miniprep DNA samples for the 4 pcDNA-FLEX-shRNA-MKP3 clones were 
verified for proper ligation of the FLEX-shRNA-MKP3 to the pcDNA vector using 
the following method. All Miniprep DNA samples (5 µL) were digested for 1 hour 
at 37°C with a freshly prepared master mix of restriction enzymes (5 µL per 
sample, prepared in bulk for several samples), which consisted of 10% BamHI-HF 
restriction enzyme, 10% XbaI restriction enzyme, 20% 10X CutSmart buffer, and 
60% water. As mentioned before, pcDNA-FLEX-shRNA-MKP3-4-1337 was only 
digested with XbaI and not digested with BamHI-HF. 
All digested DNA samples (10 µL) were then mixed with 2 µL 10X BlueJuice gel 
loading dye and run on a 1% agarose gel with 5 µL ethidium bromide for 30 minutes 
at 130 V. A TrackIt 1Kb Plus DNA Ladder (7 µL) was also run on the gel for 
comparison to the DNA fragments or bands that the samples produced. 
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The pcDNA-FLEX-shRNA-MKP3 clone samples that had proper ligation of the 
FLEX-shRNA-MKP3 to the pcDNA vector contained two distinct DNA fragments or 
bands, one band with the molecular weight of the pcDNA fragment isolated from 
the agarose gel earlier, and another band with the molecular weight of the smaller 
FLEX-shRNA-MKP3 fragment also isolated from the agarose gel earlier. Agarose 
gel analysis of several samples showed that many samples did not contain these 
two specific bands and instead contained bands of other molecular weights, 
indicating that those samples did not have proper ligation of the FLEX-shRNA-
MKP3 to the pcDNA vector. Therefore, molecular cloning of the FLEX-shRNA-
MKP3 constructs into the pcDNA vector was repeated several times until samples 
were found that contained both FLEX-shRNA-MKP3 and pcDNA fragments in the 
agarose gel analysis.  
 
Sequencing of Selected pcDNA-FLEX-shRNA-MKP3 Clones 
Once 1 such DNA sample was found for each of the 4 FLEX-shRNA-MKP3 
constructs, that sample was sent for DNA sequencing (5 µL sample in 10 µL 
water).  
 
Generation of Additional DNA for Selected pcDNA-FLEX-shRNA-MKP3 Clones 
After DNA sequence verification of the 4 chosen pcDNA-FLEX-shRNA-MKP3 
clone samples, more DNA was generated from each of these 4 samples (for further 
in vitro experiments) using Midiprep DNA extraction. For this procedure, each of 
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the Miniprep DNA samples (5 µL) for the chosen 4 pcDNA-FLEX-shRNA-MKP3 
clones were streaked on agar plates with 50 mg/mL Carbenicillin antibiotic. Plates 
were incubated at 37°C overnight for the formation of bacterial colonies with the 
pcDNA-FLEX-shRNA-MKP3 clones. 
 
Midiprep DNA Extraction of pcDNA-FLEX-shRNA-MKP3 Clones from Bacterial 
Colonies 
The pcDNA-FLEX-shRNA-MKP3 clone DNA was extracted from the bacterial 
colonies using a Plasmid Plus Midi Kit. Bacterial colonies were prepped 1 day prior 
to Midiprep by picking 1 bacterial colony from each of the pcDNA-FLEX-shRNA-
MKP3 clone plates with a toothpick (for each of the 4 pcDNA-shRNA clone plates, 
only 1 bacterial colony was grown for Midiprep). The bacterial colonies were first 
grown for several hours in Luria Broth (1 mL) and 50 mg/mL Carbenicillin antibiotic 
(1 µL) by shaking the cultures in a 37°C incubator. These bacterial cultures were 
then transferred to flasks with Luria Broth (50 mL) and 50 mg/mL Carbenicillin 
antibiotic (50 µL) for additional growth by shaking the cultures in a 37°C incubator 
overnight.  
For the Midiprep procedure the next day, each bacterial culture (50 mL) was 
centrifuged at 3400 rpm for 30 minutes, upon which the supernatant was removed 
and the bacterial pellet was resuspended in Buffer P1 (4 mL). The cells in this 
mixture were then lysed for 3 minutes using Buffer P2 (4 mL) and then neutralized 
using Buffer S3 (4 mL), after which the mixture was transferred to a Midi filter and 
allowed to settle for 10 minutes. The DNA from this mixture was then plunged out 
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from the filter and mixed with Buffer BB (2 mL). This DNA mixture was then 
transferred to a spin column under vacuum, to which Buffer ETR (700 µL) and 
wash Buffer PE (700 µL) were added. The spin column was centrifuged at 9700 
rpm for 1 minute to discard the remaining wash solution. To elute the DNA from 
the spin column, elution Buffer EB (200 µL) was added to the spin column placed 
in an Eppendorf tube. The spin column was incubated with the elution buffer for 1 
minute and then centrifuged at 9700 rpm for 1 minute to collect the pcDNA-FLEX-
shRNA-MKP3 DNA solution in the Eppendorf tube. 
 
Agarose Gel Analysis of the Final pcDNA-FLEX-shRNA-MKP3 Clone Samples 
The 4 Midiprep DNA samples for the 4 pcDNA-FLEX-shRNA-MKP3 clones were 
once again verified for proper ligation of the FLEX-shRNA-MKP3 to the pcDNA 
vector using the following method. The 4 Midiprep DNA samples (3 µg) were each 
digested for 1 hour at 37°C with BamHI-HF (1 µL) and XbaI (1 µL) restriction 
enzymes in a 20 µL reaction with water and 10X CutSmart buffer (2 µL). As 
mentioned before, pcDNA-FLEX-shRNA-MKP3-4-1337 was only digested with 
XbaI and not digested with BamHI-HF. All digested DNA samples (20 µL) were 
then mixed with 5 µL 10X BlueJuice gel loading dye and run on a 1% agarose gel 
with 5 µL ethidium bromide for 30 minutes at 130 V. A TrackIt 1Kb Plus DNA 
Ladder (7 µL) was also run on the gel for comparison to the DNA bands that the 
samples produced.   
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in vitro Studies of pcDNA-FLEX-shRNA-MKP3 Clones and Their Ability to 
Knockdown MKP3 Expression 
 
Generation of Experimental Samples 
The HEK293 cell line was used for all in vitro studies of the pcDNA-FLEX-shRNA-
MKP3 clones. HEK293 cells were cultured at 37°C with 5% CO2 in 1X DMEM with 
4.5 g/L glucose, L-glutamine and sodium pyruvate, with 10% fetal bovine serum 
and 1% of 100X penicillin streptomycin solution added to the medium. HEK293 
cells were washed with 1X PBS (pH of 7.4, made from 10X Dulbecco’s PBS without 
calcium & magnesium) prior to adding 0.05% Trypsin with 0.53mM EDTA and 1X 
sodium bicarbonate to cultures in between cell harvests. 
The 4 pcDNA-FLEX-shRNA-MKP3 clone samples (pcDNA-FLEX-shRNA-MKP3-
1-1254, pcDNA-FLEX-shRNA-MKP3-2-1096, pcDNA-FLEX-shRNA-MKP3-3-
1373, and pcDNA-FLEX-shRNA-MKP3-4-1337) were prepared as described in the 
previous section (molecular cloning of FLEX-shRNA-MKP3 constructs into the 
pcDNA3.1 vector). Undigested pcDNA vector was used for all in vitro studies. The 
Cre recombinase sample was prepared by Dr. Ole Mortensen. The Myc-MKP3 
DNA sample was prepared as follows.  
Myc-tagged MKP3 DNA was reconstituted with water (100 µL). Some of this DNA 
(1 µL) was then transformed into competent bacteria as described previously (for 
the molecular cloning of the shRNA constructs into the FLEX vector), and the 
bacterial culture was plated on an agar plate with Kanamycin antibiotic. A bacterial 
colony from this plate was cultured for Midiprep DNA extraction of the Myc-MKP3 
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DNA as described in the previous section (molecular cloning of FLEX-shRNA-
MKP3 constructs into the pcDNA3.1 vector).  
All DNA samples were regenerated for successive experiments using the same 
method: transformation of the previous DNA stock (1 µL) into competent bacteria, 
followed by culturing a bacterial colony from that plate for Midiprep DNA extraction. 
Carbenicillin antibiotic was used for all DNA samples (Cre, pcDNA, and pcDNA-
FLEX-shRNA-MKP3 clones) except for the Myc-MKP3 DNA sample, which used 
Kanamycin antibiotic since this DNA has a different selection marker. Diluted DNA 
stocks (of approximately 0.33 µg/µL) were prepared from these concentrated 
Midiprep DNA stocks for transfection into HEK293 cells.  
 
Preparation of HEK293 Cells for in vitro Studies 
HEK293 cells were plated on 12-well plates 1 day prior to transfection with DNA 
samples using the following procedure. The number of wells that were plated 
depended on the number of samples that would be transfected the next day. Plates 
were first incubated with 500 µL of 1 mg/mL PDL (diluted with water) per well for 
at least 1 hour prior to plating cells to help the cells better adhere to the plate during 
studies. Plates were also washed with PBS after the PDL step prior to plating cells. 
Cells (10 µL of a 1 mL sample gathered from cells harvested in a flask with trypsin 
and cell culture medium) were counted under the microscope using a 
hemocytometer. The number of cells in the 16-square grid were multiplied by 
10,000 to approximate the number of cells contained within the 1 mL sample. This 
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number of cells was used to calculate how much volume of the total harvested cell 
sample would be needed to plate the 12-well plates, depending on the cell 
concentration desired per well and the number of wells that would be plated. For 
example, if 500,000 cells would be plated per well for all 12 wells on a plate, the 
total number of cells needed for all wells of a 12-well plate would be 6,000,000 
cells. This number was then divided by the number of cells in the 1 mL sample (as 
determined by the hemocytometer counting), which gave the volume of cell mixture 
needed from the total harvested cell mixture. The volume of cell mixture isolated 
for plating was further diluted with cell culture medium up to a total volume of 12 
mL to use for plating all 12 wells, since each well would be plated with 1 mL of cell 
mixture. Plated cells were incubated overnight at 37°C to allow cells to attach to 
the plate prior to transfection the next day. 
 
Transfection of HEK293 Cells with DNA Samples 
The plated HEK293 cells were checked for confluency under the microscope the 
next day and transfected with the experimental DNA samples using the following 
procedure. Just prior to transfection, the cell culture medium for the plated cells 
was changed with fresh medium. The LipoJet in vitro Transfection Kit was used for 
all HEK293 cell transfections. 
A diluted 1X transfection buffer mixture was prepared in slight excess (ex. 1300 µL 
was prepared in excess for 12 samples) for the total number of transfection 
samples using 20% 5X LipoJet Transfection Buffer and 80% water. Each 
transfection sample received 100 µL of this 1X transfection buffer mixture, to which 
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the experimental DNA sample was added. Each transfection sample was 
thoroughly mixed (by flicking the Eppendorf tube) before and after the addition of 
the LipoJet Transfection Reagent, after which the samples were incubated at room 
temperature for a minimum of 10 minutes (but no longer than 20 minutes) prior to 
adding the samples slowly to the plated cells.  
Cells with the transfection samples were incubated for 2 nights at 37°C prior to 
lysing cells for protein analysis. On the day of cell lysis, a cell lysis buffer was 
prepared in excess for the total number of cell samples, which contained 25% 
NuPAGE 4X LDS sample buffer, 10% 0.5 mM Dithiothreitol reducing agent, and 
65% water. Each cell sample received 200 µL of cell lysis buffer, after which 
samples were sonicated to reduce the viscosity of the lysed cell sample. Samples 
were then used for Western Blot analysis or frozen for later analysis. 
 
Western Blot Analysis of in vitro Samples for Protein Expression 
Western Blot was performed for all lysed and sonicated HEK293 cell samples 
using the following procedure in order to examine the expression of key proteins 
such as MKP3. Samples were first heated at 65°C for 10 minutes, upon which 10 
µL of each sample was loaded onto a 15-well NuPAGE Novex 4-12% Bis-Tris Gel. 
A prestained broad range protein marker (5 µL) was also loaded onto the gel. 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was run 
at 200 V for approximately 50 minutes with 1X Running Buffer prepared from 5% 
20X NuPAGE MOPS SDS Running Buffer and 95% water. 
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After SDS-PAGE, the protein bands on the gel were transferred onto an 
Immobilon-FL PVDF membrane that was presoaked with methanol, both of which 
were sandwiched in between Blotting Filter Paper. Transfer was run at 35 V for 1.5 
hours with 1X Transfer Buffer prepared from 5% 20X NuPAGE Transfer Buffer, 
water, and 10% methanol if running 1 gel or 20% methanol if running 2 gels. Both 
SDS-PAGE and transfer steps were conducted using the XCell SureLock Mini-Cell 
Western Blot apparatus. 
After transfer of the protein bands onto the membrane, the membrane (with the gel 
or protein side facing upwards) was first rinsed with PBS then blocked with 
Odyssey blocking buffer on a rocker at room temperature for at least 1 hour. The 
blocking buffer was then discarded and the membrane was incubated with a 
primary antibody solution on a rocker overnight at 4°C. Several different primary 
antibodies were used for these studies, as mentioned below. All primary antibody 
solutions were made in 5 mL of 0.5% Tween-20 in PBS (PBS-T).  
To examine MKP3 expression in the samples, a mouse Myc epitope-tagged MKP3 
antibody was used (5 µL in 5 mL PBS-T for a 1:1,000 dilution). To examine RFP 
expression, a mouse RFP tag antibody was used (5 µL in 5 mL PBS-T for a 1:1,000 
dilution). To normalize protein expression for Myc-MKP3 and RFP, the expression 
for a control housekeeping protein, actin, was also examined using a rabbit actin 
antibody (5 µL in 5 mL PBS-T for a 1:1,000 dilution) in the same primary antibody 
solution as either the Myc-MKP3 or RFP antibody. Therefore, there would be either 
mouse Myc-MKP3 antibody or mouse RFP antibody in the same solution as rabbit 
actin antibody. Antibodies from two different species (mouse and rabbit) could be 
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used in the same antibody solution, however two antibodies of the same species 
could never be combined in the same antibody solution. 
The next day, the primary antibody solution was discarded and the membrane was 
washed 3 times with PBS-T on a rocker at room temperature for 10 minutes each 
(the previous wash solution was discarded in between wash steps). The 
membrane was then incubated with a secondary antibody solution on a rocker at 
room temperature for 1 hour, and which the membrane was again washed 3 times 
with PBS-T on a rocker at room temperature for 10 minutes each. Since the 
primary antibody solution consisted of antibodies from both mouse and rabbit 
species, the secondary antibody solution was prepared with both an Anti-Mouse 
IgG DyLight 680 Conjugate (1 µL for a 1:10,000 dilution) and an Anti-Rabbit IgG 
DyLight 800 4X PEG Conjugate (1 µL for a 1:10,000 dilution) in the same 10 mL 
solution of PBS-T. After the final wash step, the membrane was stored in PBS-T 
for imaging analysis. Membranes were imaged and analyzed for protein 
expression (using band density measurements) with the LI-COR Image Studio 
software, version 4.0.21. 
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Optimization of HEK293 Cell Concentration for in vitro Studies 
To determine what optimal HEK293 cell concentration per well of a 12-well plate 
would result in the best possible RFP and Myc-tagged MKP3 protein expression, 
HEK293 cell concentration was optimized through the following experiment. 
Note: 2 µL of LipoJet Transfection Reagent was used for all of these transfections. 
The following cell concentrations were tested for plating in wells of a 12-well plate: 
125,000; 250,000; 500,000 and 1,000,000. 
The following 3 DNA samples were transfected for each cell concentration: 
2 µg pcDNA—Negative control for both RFP and Myc-tagged MKP3 expression. 
(Since there is no Myc-MKP3 DNA transfected, no Myc-MKP3 expression is 
expected. Similarly, since no pcDNA-FLEX-shRNA-MKP3 clone DNA is 
transfected, no RFP expression is expected.) 
2 µg Myc-MKP3—Positive control for Myc-tagged MKP3 expression (to determine 
which cell concentration gives the best expression of this protein). 
2 µg pcDNA-FLEX-shRNA-MKP3-2-1096—Positive control for RFP expression (to 
determine which cell concentration gives the best expression of this protein). 
All samples and cell concentrations were also tested for PDL conditions—i.e. 
plating cells with PDL versus not plating cells with PDL to determine which 
condition resulted in better RFP or Myc-tagged MKP3 protein expression. 
Western Blot analysis for actin and Myc-tagged MKP3 expression was conducted 
for all samples that were transfected with either pcDNA or Myc-MKP3 DNA. 
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Western Blot analysis for actin and RFP expression was conducted for all samples 
that were transfected with either pcDNA or the pcDNA-FLEX-shRNA-MKP3-2-
1096 clone DNA. 
The following table shows the 24 experimental samples for this part of the study: 
# of Cells Cells Plated with PDL Cell Plated without PDL 
125,000 pcDNA MKP3 shRNA 2 pcDNA MKP3 shRNA 2 
250,000 pcDNA MKP3 shRNA 2 pcDNA MKP3 shRNA 2 
500,000 pcDNA MKP3 shRNA 2 pcDNA MKP3 shRNA 2 
1,000,000 pcDNA MKP3 shRNA 2 pcDNA MKP3 shRNA 2 
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Optimization of Transfection Conditions for in vitro Studies 
To further determine the transfection conditions that would result in the best 
possible Myc-tagged MKP3 protein expression, the following 2 transfections 
conditions were optimized in this experiment: 
1) Amount of DNA Transfected into HEK293 Cells 
2) The ratio of DNA Amount (µg) to LipoJet Transfection Reagent Amount (µL) 
The following DNA transfection amounts were tested in this experiment: 
0.5 µg DNA, 1 µg DNA, 2 µg DNA, and 3 µg DNA 
The following DNA:Transfection Reagent Ratios were tested in this experiment: 
1:1 ratio, 1:2 ratio, and 1:3 ratio of DNA amount to transfection reagent amount 
After optimization, the pcDNA-FLEX-shRNA-MKP3 clones would be transfected in 
a 2:1 ratio of DNA amount with the Myc-MKP3 DNA. The positive control would be 
a 2:1 ratio of pcDNA to Myc-MKP3 DNA. Only this positive control sample was 
used for all transfections in this optimization experiment. A HEK293 cell 
concentration of 500,000 cells per well of a 12-well plate was used for all 
transfections, as determined by the previous cell concentration optimization 
experiment. All samples underwent Western Blot analysis for actin and Myc-
tagged MKP3 protein expression. 
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The following table shows the 12 experimental samples for this part of the study: 
Sample # DNA 
Amount 
DNA : 
LipoJet 
LipoJet 
Amount 
pcDNA 
Amount 
Myc-MKP3 
Amount 
1 0.5 µg 1:1 ratio 0.5 µL 0.33 µg 0.165 µg 
2 0.5 µg 1:2 ratio 1 µL 0.33 µg 0.165 µg 
3 0.5 µg 1:3 ratio 1.5 µL 0.33 µg 0.165 µg 
4 1 µg 1:1 ratio 1 µL 0.66 µg 0.33 µg 
5 1 µg 1:2 ratio 2 µL 0.66 µg 0.33 µg 
6 1 µg 1:3 ratio 3 µL 0.66 µg 0.33 µg 
7 2 µg 1:1 ratio 2 µL 1.33 µg 0.66 µg 
8 2 µg 1:2 ratio 4 µL 1.33 µg 0.66 µg 
9 2 µg 1:3 ratio 6 µL 1.33 µg 0.66 µg 
10 3 µg 1:1 ratio 3 µL 2 µg 1 µg 
11 3 µg 1:2 ratio 6 µL 2 µg 1 µg 
12 3 µg 1:3 ratio 9 µL 2 µg 1 µg 
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The Effect of pcDNA-FLEX-shRNA-MKP3 Clones on MKP3 Knockdown 
To determine how effective the pcDNA-FLEX-shRNA-MKP3 clones are at 
silencing or knocking down MKP3 protein expression in vitro, these clone DNA 
samples were combined with Myc-MKP3 DNA and both DNA samples were 
transfected in HEK293 cells. All 4 clone DNA samples were tested (pcDNA-FLEX-
shRNA-MKP3-1-1254, pcDNA-FLEX-shRNA-MKP3-2-1096, pcDNA-FLEX-
shRNA-MKP3-3-1373, and pcDNA-FLEX-shRNA-MKP3-4-1337), and it was 
expected that these samples would have decreased expression of MKP3 
compared to the positive control sample. 
As mentioned in the previous section, the pcDNA-FLEX-shRNA-MKP3 clones 
were transfected in a 2:1 ratio of DNA amount with the Myc-MKP3 DNA. The 
positive control did not contain any clone DNA and instead contained a 2:1 ratio of 
pcDNA to Myc-MKP3 DNA. The negative control sample consisted of no DNA 
being transfected in that sample, so no MKP3 expression was expected. All 
samples underwent Western Blot analysis for actin and Myc-tagged MKP3 protein 
expression, as well as actin and RFP expression. 
The following transfection conditions were used for these studies, as determined 
by the previous optimization experiments. A HEK293 cell concentration of 500,000 
cells per well of a 12-well plate was used for all transfections. Cells were 
transfected with 2 µg DNA and 4 µL LipoJet transfection reagent (a 1:2 ratio of 
DNA amount to transfection reagent amount).  
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The following table shows the 6 experimental samples for this part of the study: 
Sample Number DNA Amounts Used for Transfection 
1 (Negative Control) No DNA Added 
2 (Positive Control) 0.66 µg Myc-MKP3 + 1.33 µg pcDNA 
3 0.66 µg Myc-MKP3 + 1.33 µg shRNA 1 
4 0.66 µg Myc-MKP3 + 1.33 µg shRNA 2 
5 0.66 µg Myc-MKP3 + 1.33 µg shRNA 3 
6 0.66 µg Myc-MKP3 + 1.33 µg shRNA 4 
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The Elimination of MKP3 Knockdown with Cre and pcDNA-FLEX-shRNA-MKP3 
Clones 
To further study the effect of Cre on MKP3 knockdown by the 4 pcDNA-FLEX-
shRNA-MKP3 clones, the following experiment was designed. As mentioned in the 
Introduction, Cre will flip the direction of constructs that are flanked by LoxP sites 
(which are contained in the FLEX vector). Since all 4 of the pcDNA-FLEX-shRNA-
MKP3 clones used in this experiment were constructed with the shRNAs in the 
forward direction, Cre will flip the direction of these shRNAs, causing them not to 
be expressed and therefore eliminating the knockdown effect on MKP3. Thus, 
samples containing Cre were expected to have an increased expression of MKP3 
compared to the samples containing pcDNA, where the shRNAs in the latter 
samples will still be expressed and therefore a knockdown effect on MKP3 is 
expected in these latter samples. 
All samples received the Myc-MKP3 DNA in a 1:2 ratio with the pcDNA-FLEX-
shRNA-MKP3 clones (as described in the previous experiment), except for the 
negative control sample which was transfected with no DNA (no MKP3 expression 
is expected in this sample). The positive control sample, similar to the last 
experiment, did not contain any pcDNA-FLEX-shRNA-MKP3 clone DNA and only 
contained the Myc-MKP3 DNA and pcDNA. The same transfection conditions were 
used as the last experiment (HEK293 cell concentration of 500,000 per well of a 
12-well plate, and transfection with 2 µg DNA and 4 µL LipoJet transfection 
reagent). Also similar to the last experiment, all samples underwent Western Blot 
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analysis for actin and Myc-tagged MKP3 protein expression, as well as actin and 
RFP expression. 
 
The following table shows the 10 experimental samples for this part of the study: 
 
Sample Number DNA Amounts Used for Transfection 
1 (Negative Control) No DNA Added 
2 (Positive Control) 0.4 µg Myc-MKP3 + 1.6 µg pcDNA 
3 0.4 µg Myc-MKP3 + 0.8 µg shRNA 1 + 0.8 µg pcDNA 
4 0.4 µg Myc-MKP3 + 0.8 µg shRNA 1 + 0.8 µg Cre 
5 0.4 µg Myc-MKP3 + 0.8 µg shRNA 2 + 0.8 µg pcDNA 
6 0.4 µg Myc-MKP3 + 0.8 µg shRNA 2 + 0.8 µg Cre 
7 0.4 µg Myc-MKP3 + 0.8 µg shRNA 3 + 0.8 µg pcDNA 
8 0.4 µg Myc-MKP3 + 0.8 µg shRNA 3 + 0.8 µg Cre 
9 0.4 µg Myc-MKP3 + 0.8 µg shRNA 4 + 0.8 µg pcDNA 
10 0.4 µg Myc-MKP3 + 0.8 µg shRNA 4 + 0.8 µg Cre 
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Statistical Analyses 
Western Blot images were analyzed for protein expression using the band density 
measurements in the LI-COR Image Studio software. Band density measurements 
for both RFP and MKP3 protein expression were first normalized to actin protein 
expression, and then all samples were expressed as percent of the positive control 
sample (only for MKP3 expression but not for RFP expression since RFP 
expression did not have a positive control for comparison). These measurements 
were further analyzed for statistical significance using GraphPad Prism version 5 
for PC. One-way ANOVA with a Dunnett post hoc test was used to determine 
statistical significance of the MKP3 expression data when compared to the positive 
control sample that did not contain any pcDNA-FLEX-shRNA-MKP3 clones. One-
way ANOVA with a Bonferroni post hoc test was used to determine statistical 
significance of both MKP3 and RFP expression in between groups of the shRNA 
samples, i.e. for comparison of shRNA samples with Cre recombinase vs. shRNA 
samples without Cre recombinase. P<0.05 was considered statistically significant.  
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RESULTS 
 
Molecular Cloning of shRNA Constructs into FLEX-RFP-shRNA DNA Vector 
 
Sequencing Analysis of FLEX-shRNA-MKP3 Constructs 
The DNA sequences from the 12 FLEX-shRNA-MKP3 samples sent for 
sequencing were analyzed in the following manner. For the forward direction DNA 
sequences (samples containing the forward primer), it was verified that the 
sequences contained the XbaI restriction enzyme sequence (TCTAGA) followed 
by the BamHI restriction enzyme sequence (GGATCC), with several nucleotides 
in between the XbaI and BamHI sequences. For the reverse direction DNA 
sequences (samples containing the reverse primer), it was verified that the 
sequences contained the EcoRI restriction enzyme sequence (GAATTC) followed 
by the specific shRNA sequence for each of the 4 shRNAs, with several 
nucleotides in between these two sequences. Sequencing results showed that 2 
out of the 3 DNA samples for each of the 4 FLEX-shRNAs contained the correct 
shRNA sequence, indicating that these DNA samples could be used for further 
experiments (i.e. further molecular cloning of the FLEx-shRNA-MKP3 constructs 
into the pcDNA vector) since the shRNAs had successfully ligated into the FLEX 
DNA vector for these samples. 
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Molecular Cloning of FLEX-shRNA-MKP3 Constructs into the pcDNA3.1 Vector 
 
Sequencing Analysis of pcDNA-FLEX-shRNA-MKP3 Clones 
The 4 pcDNA-FLEX-shRNA-MKP3 clone samples sent for sequencing (pcDNA-
FLEX-shRNA-MKP3-1-1254, pcDNA-FLEX-shRNA-MKP3-2-1096, pcDNA-FLEX-
shRNA-MKP3-3-1373, and pcDNA-FLEX-shRNA-MKP3-4-1337) showed the 
presence of the BamHI-HF restriction enzyme sequence, as well as the presence 
of the red fluorescent protein (RFP) sequence, indicating that the DNA sample 
contained the shRNA construct since the RFP sequence falls right before the 
shRNA sequence.  
 
Agarose Gel Analysis of the Final pcDNA-FLEX-shRNA-MKP3 Clone Samples 
Shown in Figure 12 is the agarose gel analysis of the 4 pcDNA-FLEX-shRNA-
MKP3 clone samples (pcDNA-FLEX-shRNA-MKP3-1-1254, pcDNA-FLEX-
shRNA-MKP3-2-1096, pcDNA-FLEX-shRNA-MKP3-3-1373, and pcDNA-FLEX-
shRNA-MKP3-4-1337) generated from Midiprep, which was conducted to verify 
the ligation of the FLEX-shRNA-MKP3 constructs to the pcDNA vector.  
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Figure 12. Agarose gel analysis of pcDNA-FLEX-shRNA-MKP3 clones after 
digestion with restriction enzymes verifies that all FLEX-shRNA-MKP3 constructs 
properly ligated to pcDNA (since all digested pcDNA-FLEX-shRNA-MKP3 clone 
samples contain DNA fragments for both FLEX-shRNA-MKP3 and pcDNA). 
 
Agarose gel analysis of the 4 pcDNA-FLEX-shRNA-MKP3 clones showed that all 
samples contained the desired two DNA bands, one band with the molecular 
weight (approximately 5000 base pairs) of the pcDNA fragment isolated from the 
agarose gel earlier, and another band with the molecular weight (approximately 
1000 base pairs) of the smaller FLEX-shRNA-MKP3 fragment also isolated from 
the agarose gel earlier. This indicated that all 4 pcDNA-FLEX-shRNA-MKP3 clone 
samples contained both the FLEX-shRNA-MKP3 construct as well as the pcDNA 
vector, verifying that all of these samples had proper ligation of the FLEX-shRNA-
MKP3 construct to the pcDNA vector. This meant that these 4 pcDNA-FLEX-
shRNA-MKP3 clone samples could be used for further in vitro experiments. 
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in vitro Studies of pcDNA-FLEX-shRNA-MKP3 Clones and Their Ability to 
Knockdown MKP3 Expression 
 
Optimization of HEK293 Cell Concentration for in vitro Studies 
Shown in Figure 13 is the Western Blot analysis of HEK293 cell cultures with 
various different cell concentrations, which was conducted in order to determine 
the HEK293 cell concentration that results in the best Myc-tagged MKP3 protein 
expression as well as RFP expression. 
 
 
Figure 13. Optimization of HEK293 Cell Concentration. Western Blot analysis of 
various different HEK293 cell concentrations showed that the best RFP and Myc-
tagged MKP3 protein expression was achieved with a cell concentration of 
500,000 cells per well of a 12-well plate. Western Blot images are representative 
of 2 blots from 2 separate in vitro experiments. 
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Optimization of HEK293 cell concentration showed that a HEK293 cell 
concentration of 500,000 cells per well of a 12-well plate resulted in the best RFP 
and Myc-tagged MKP3 protein expression. In fact, Myc-tagged MKP3 protein 
expression was only seen for the positive control samples (transfected with Myc-
MKP3 DNA) that contained 500,000 cell concentration, whereas positive control 
samples that contained 125,000, 250,000, or 1,000,000 cell concentration did not 
show any Myc-tagged MKP3 protein expression. 
RFP expression was seen in positive control samples (transfected with the pcDNA-
FLEX-shRNA-MKP3-2-1096 clone, referred to as shRNA2) that contained 250,000 
or 500,000 cell concentration, where the positive control samples that contained 
500,000 cell concentration had much better RFP expression than the positive 
control samples that contained 250,000 cell concentration. Positive control 
samples that contained 125,000 or 1,000,000 cell concentration did not show any 
RFP expression. 
As expected, no RFP or Myc-tagged MKP3 protein expression was observed for 
negative control samples that were transfected with pcDNA. Also as expected, the 
actin protein expression increased as the cell concentration of the different 
samples increased. Overall, the HEK293 cell survival seemed slightly better with 
PDL on the plate prior to cell plating, since this would help the cells better attach 
to the plate. Furthermore, the positive control samples that were plated with PDL 
showed slightly better RFP or Myc-tagged MKP3 protein expression than the 
positive control samples that were not plated with PDL. 
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Therefore, it was determined from this optimization experiment that all further in 
vitro experiments in this study would be conducted with a HEK293 cell 
concentration of 500,000 cells per well of a 12-well plate with PDL coated on the 
plate prior to cell plating. 
 
Optimization of Transfection Conditions for in vitro Studies 
Shown in Figure 14 is the Western Blot analysis of HEK293 cell cultures with 
different transfection conditions (i.e. the amount of DNA transfected, as well as the 
ratio of that DNA amount to the amount of transfection reagent used), which was 
conducted to determine which transfection conditions would result in the best Myc-
tagged MKP3 protein expression for the positive control sample (containing just 
pcDNA and Myc-MKP3 DNA). 
 
 
Figure 14. Optimization of Transfection Conditions. Western Blot analysis of 
HEK293 cells with various different amounts of DNA transfected and different 
ratios of DNA amount to transfection reagent amount showed that the best Myc-
tagged MKP3 protein expression was achieved with 2 µg of DNA transfected and 
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a 1:2 ratio of that DNA amount to the amount of transfection reagent used in that 
sample (4 µL). Western Blot images are representative of 4 blots from 4 separate 
in vitro experiments. 
 
Optimization of transfection conditions showed that 2 µg of DNA transfected, as 
well as a 1:2 ratio of that DNA amount to the amount of transfection reagent used 
in that sample (4 µL), resulted in the best Myc-tagged MKP3 protein expression. 
No Myc-tagged MKP3 protein expression was observed for any of the samples 
transfected with 0.5 µg DNA. Samples transfected with 1 µg DNA showed very 
little Myc-tagged MKP3 protein expression (except for the 1 µg sample that 
contained a 1:3 ratio of DNA amount to transfection reagent amount, which 
showed no Myc-tagged MKP3 protein expression). 
Samples transfected with 2 µg DNA and a 1:1 ratio of DNA amount to transfection 
reagent amount showed very faint Myc-tagged MKP3 protein expression, while 
samples transfected with 2 µg DNA and a 1:3 ratio did not show any Myc-tagged 
MKP3 protein expression. For samples transfected with 3 µg DNA, Myc-tagged 
MKP3 protein expression was seen only for the samples that contained a 1:2 ratio 
of DNA amount to transfection reagent amount, but this protein expression was 
not as strong as the signal seen with the 2 µg sample with a 1:2 ratio of DNA 
amount to transfection reagent amount. All other 3 µg samples did not show any 
Myc-tagged MKP3 protein expression. Actin protein expression seemed fairly 
constant among all of the samples (as expected). 
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Therefore, it was determined from this optimization experiment that all further in 
vitro experiments in this study would be conducted with 2 µg of DNA transfected 
and 4 µL of transfection reagent used, giving a final 1:2 ratio of DNA amount to 
transfection reagent amount. 
 
The Effect of pcDNA-FLEX-shRNA-MKP3 Clones on MKP3 Knockdown 
Shown in Figure 15 is the Western Blot analysis of HEK293 cell cultures 
transfected with the 4 pcDNA-FLEX-shRNA-MKP3 clones, which was conducted 
for Myc-tagged MKP3 protein expression in order to determine the amount of 
MKP3 silencing induced by the pcDNA-FLEX-shRNA-MKP3 clones. 
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Figure 15. MKP3 silencing by pcDNA-FLEX-shRNA-MKP3 clones. Western Blot 
analysis of HEK293 cells transfected with pcDNA-FLEX-shRNA-MKP3 clones 
showed that shRNA1-1254 induced the most silencing of Myc-tagged MKP3 
protein expression (***p<0.001), though shRNA4-1337 also significantly reduced 
Myc-tagged MKP3 protein expression (*p<0.05). Western Blot images are 
representative of 8 blots from 8 separate in vitro experiments. Band densities of all 
samples were normalized to actin protein expression. For each experimental 
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group, quantitative data represents the average Myc-tagged MKP3 protein 
expression for all samples in that group ± standard error. Each sample was 
expressed as a percentage of the positive control sample (100%) containing just 
pcDNA and Myc-MKP3 DNA (no pcDNA-FLEX-shRNA-MKP3 clones). Any Myc-
tagged MKP3 protein expression seen in the negative control sample (transfected 
with no DNA) was subtracted as background from all of the other samples. 
 
Western Blot analysis of HEK293 cell cultures transfected with pcDNA-FLEX-
shRNA-MKP3 clones showed that Myc-tagged MKP3 protein expression 
significantly decreased in the samples containing either pcDNA-FLEX-shRNA-
MKP3-1-1254 (referred to as shRNA1-1254, ***p<0.001) or pcDNA-FLEX-shRNA-
MKP3-4-1337 (referred to as shRNA4-1337, *p<0.05), where pcDNA-FLEX-
shRNA-MKP3-1-1254 (shRNA1-1254) induced the most MKP3 silencing (by 
approximately 50% from the positive control sample). However, samples 
containing either pcDNA-FLEX-shRNA-MKP3-2-1096 or pcDNA-FLEX-shRNA-
MKP3-3-1373 did not exhibit significant reduction of Myc-tagged MKP3 protein 
expression when compared to the positive control sample which did not contain 
any pcDNA-FLEX-shRNA-MKP3 clone DNA.  
Shown in Figure 16 is the Western Blot analysis of the same HEK293 cell cultures 
just discussed, transfected with the 4 pcDNA-FLEX-shRNA-MKP3 clones, which 
was conducted for RFP expression in order to determine whether or not the 
samples containing the pcDNA-FLEX-shRNA-MKP3 clones were actually 
expressing the shRNA in the clones. 
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Figure 16. RFP expression of pcDNA-FLEX-shRNA-MKP3 clones. Western Blot 
analysis of HEK293 cells transfected with pcDNA-FLEX-shRNA-MKP3 clones 
showed RFP expression in all samples, which confirmed that the shRNAs were 
being expressed in the samples. Western Blot images are representative of 8 blots 
from 8 separate in vitro experiments. Band densities were normalized to actin 
protein expression. For each experimental group, quantitative data represents the 
average RFP expression for samples in that group ± standard error.  
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Western Blot analysis of HEK293 cell cultures transfected with pcDNA-FLEX-
shRNA-MKP3 clones confirmed that all 4 experimental samples were indeed 
expressing the shRNA in the pcDNA-FLEX-shRNA-MKP3 clones, which was 
indicated by RFP expression in all 4 samples. However, this RFP expression level 
varied amongst the 4 different samples since each of them contained a different 
shRNA from one another (targeting different regions of the reading frame on the 
MKP3 gene). Samples containing either pcDNA-FLEX-shRNA-MKP3-1-1254 
(referred to as shRNA1-1254) or pcDNA-FLEX-shRNA-MKP3-3-1373 (referred to 
as shRNA3-1373) expressed similar levels of RFP, while samples containing 
pcDNA-FLEX-shRNA-MKP3-2-1096 (referred to as shRNA2-1096) expressed 
slightly lower levels of RFP. Samples containing pcDNA-FLEX-shRNA-MKP3-4-
1337 (referred to as shRNA4-1337) showed markedly less RFP expression. 
 
The Elimination of MKP3 Knockdown with Cre and pcDNA-FLEX-shRNA-MKP3 
Clones 
Shown in Figure 17 is the Western Blot analysis of HEK293 cell cultures 
transfected with the 4 pcDNA-FLEX-shRNA-MKP3 clones in the presence or 
absence of Cre, which was conducted for Myc-tagged MKP3 protein expression in 
order to study the amount of MKP3 silencing induced by the pcDNA-FLEX-shRNA-
MKP3 clones in the absence of Cre, as well as to study how the presence of Cre 
affects MKP3 silencing by the pcDNA-FLEX-shRNA-MKP3 clones. 
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Figure 17. The Cre dependence of MKP3 silencing. Western Blot analysis of 
HEK293 cells transfected with pcDNA-FLEX-shRNA-MKP3 clones showed that 
Cre eliminated shRNA-induced Myc-tagged MKP3 silencing, though this 
elimination effect was only found to be significant for shRNA1-1254 (**p<0.01) and 
shRNA4-1337 (*p<0.05). It was also confirmed that shRNA1-1254 induced the 
most silencing of Myc-tagged MKP3 protein expression (***p<0.001), though 
shRNA4-1337 also significantly reduced Myc-tagged MKP3 protein expression 
(**p<0.01). Western Blot images are representative of 6 blots from 6 separate in 
vitro experiments. Band densities of all samples were normalized to actin protein 
expression. For each experimental group, quantitative data represents the 
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average Myc-tagged MKP3 protein expression for all samples in that group ± 
standard error. Each sample was expressed as a percentage of the positive control 
sample (100%) containing just pcDNA and Myc-MKP3 DNA (no pcDNA-FLEX-
shRNA-MKP3 clones). Any Myc-tagged MKP3 protein expression seen in the 
negative control sample (transfected with no DNA) was subtracted as background 
from all of the other samples. 
 
Western Blot analysis of HEK293 cell cultures transfected with pcDNA-FLEX-
shRNA-MKP3 clones in the absence of Cre showed that similar to the previous set 
of experiments, Myc-tagged MKP3 protein expression significantly decreased in 
the samples containing either pcDNA-FLEX-shRNA-MKP3-1-1254 (referred to as 
shRNA1-1254, ***p<0.001) or pcDNA-FLEX-shRNA-MKP3-4-1337 (referred to as 
shRNA4-1337, **p<0.01), where once again, pcDNA-FLEX-shRNA-MKP3-1-1254 
(shRNA1-1254) induced the most amount of MKP3 silencing. Also similar to the 
previous set of experiments, samples containing either pcDNA-FLEX-shRNA-
MKP3-2-1096 or pcDNA-FLEX-shRNA-MKP3-3-1373 did not significantly reduce 
Myc-tagged MKP3 protein expression when compared to the positive control 
sample which did not contain any pcDNA-FLEX-shRNA-MKP3 clone DNA.  
However, these MKP3 silencing effects are reversed and eliminated by the 
presence of Cre in the pcDNA-FLEX-shRNA-MKP3 clone samples, though this 
elimination effect was only found to be significant for shRNA1-1254 (**p<0.01) and 
shRNA4-1337 (*p<0.05). Since all of the pcDNA-FLEX-shRNA-MKP3 clones 
express the shRNAs in the forward direction, the expression of the shRNAs and 
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their ability to silence MKP3 is unaffected in samples that do not contain Cre. 
However, in the samples that contain Cre, Cre flips the orientation of the shRNAs, 
resulting in them being expressed in the reverse direction such that the shRNAs 
will no longer be able to silence MKP3. Thus, the presence of Cre affects and alters 
an shRNA’s ability to silence MKP3, making MKP3 silencing Cre dependent due 
to the directionality of the shRNAs. 
 
Shown in Figure 18 is the Western Blot analysis of the same HEK293 cell cultures 
as just discussed previously, transfected with the 4 pcDNA-FLEX-shRNA-MKP3 
clones in the presence or absence of Cre, which was conducted for RFP 
expression in order to study how the presence or absence of Cre affects the 
amount of RFP expression produced by the pcDNA-FLEX-shRNA-MKP3 clones.  
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Figure 18. The Cre dependence of RFP expression. Western Blot analysis of 
HEK293 cells transfected with pcDNA-FLEX-shRNA-MKP3 clones showed that 
Cre reduced RFP expression (indicating less shRNA expression), though no 
significance of this reduction was found. Western Blot images are representative 
of 6 blots from 6 separate in vitro experiments. Band densities of all samples were 
normalized to actin protein expression. For each experimental group, quantitative 
data represents the average RFP expression for all samples in that group ± 
standard error.  
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Similar to the previous RFP expression analysis, Western Blot analysis of HEK293 
cell cultures transfected with pcDNA-FLEX-shRNA-MKP3 clones confirmed that all 
samples were expressing the shRNA in the pcDNA-FLEX-shRNA-MKP3 clones, 
since this was indicated by RFP expression in all samples. Samples that did not 
contain Cre showed a similar pattern of RFP expression compared to the previous 
set of experiments without Cre, where samples containing pcDNA-FLEX-shRNA-
MKP3-1-1254 (referred to as shRNA1-1254), pcDNA-FLEX-shRNA-MKP3-2-1096 
(referred to as shRNA2-1096), or pcDNA-FLEX-shRNA-MKP3-3-1373 (referred to 
as shRNA3-1373) showed similar levels of RFP expression, while samples 
containing pcDNA-FLEX-shRNA-MKP3-4-1337 (referred to as shRNA4-1337) 
showed less RFP expression. 
However, the presence of Cre decreased RFP expression in all samples, though 
this reduction was not found to be significant by statistical analysis. As discussed 
before when analyzing the same samples for Myc-tagged MKP3 protein 
expression, Cre flips the forward orientation of the shRNAs in the pcDNA-FLEX-
shRNA-MKP3 clones, making them expressed in the reverse direction and 
therefore compromising their ability to silence MKP3. Therefore, the presence of 
Cre decreases shRNA expression in all samples, which correlates directly with the 
reduction of RFP expression seen in the same samples. Thus in addition to Myc-
tagged MKP3 protein expression, RFP expression is also Cre dependent or 
affected by the presence or absence of Cre. 
  
64 
 
DISCUSSION 
 
The goal of this study was to develop an RNAi-based genetic tool that would utilize 
a miR30-based shRNA vector to target the MKP3 gene and silence its expression, 
with the eventual goal of being able to silence MKP3 expression in a cell-specific 
or circuit-specific manner by using Cre recombinase technology. Current genetic 
and pharmacological tools lack the ability to modulate intracellular signaling 
pathways in vivo in a cell-specific or circuit-specific manner, and therefore the 
development of such a genetic tool could be used to study any protein of interest 
by modulating its expression in a cell-specific manner without affecting its 
expression elsewhere. For example, this genetic tool could be used to study the 
role of long term plasticity changes in pathologies of the brain, such as drug 
addiction, psychiatric diseases, and neurodegenerative diseases. Our lab is 
interested in using this genetic tool in vivo to study the role of MKP3 in cocaine 
addiction by specifically modulating and silencing MKP3 expression in 
dopaminergic neurons with the use of transgenic rats that express Cre 
recombinase exclusively in TH expressing cells, which are indicative of 
dopaminergic neurons. 
The primary aim of this project was to develop this genetic tool starting with 4 
distinct shRNAs that target different regions of the MKP3 gene reading frame, and 
to systematically determine which one of these shRNAs was the most effective at 
silencing MKP3 expression by studying their ability to knockdown MKP3 
expression in vitro. A significant portion of this project was devoted to optimizing 
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the experimental conditions for the in vitro assays that were used to confirm the 
validity and effectiveness of this genetic tool. The most effective shRNA can then 
be used in future studies to develop an AAV vector and further study MKP3 
silencing in vivo in order to study MKP3’s role in cocaine addiction. 
Each of the 4 shRNA constructs were first cloned into a FLEX-RFP-shRNA DNA 
vector since it contained the incompatible lox P sites needed to utilize Cre 
recombinase technology. This formed 4 FLEX-shRNA-MKP3 clones, which were 
verified by DNA sequencing to ensure that the shRNA constructs were properly 
cloned and present in the FLEX-shRNA-MKP3 clones.  
These 4 FLEX-shRNA-MKP3 clones were then further cloned into a pcDNA3.1 
vector which contained the CMV promoter needed to express the shRNA 
constructs, forming 4 pcDNA-FLEX-shRNA-MKP3 clones. Agarose gel analysis 
was used to verify the proper cloning and ligation of the FLEX-shRNA-MKP3 
constructs to the pcDNA vector, where digestion of the 4 pcDNA-FLEX-shRNA-
MKP3 clones with restriction enzymes showed the presence of both the FLEX-
shRNA-MKP3 fragment as well as the pcDNA fragment, therefore verifying the 
proper cloning of the FLEX-shRNA-MKP3 constructs into the pcDNA vector. DNA 
sequencing was also used to further verify the proper cloning of the FLEX-shRNA-
MKP3 constructs into the pcDNA vector, which showed the presence of the RFP 
sequence and therefore indicating that the pcDNA-FLEX-shRNA-MKP3 clones 
contained the shRNA constructs since the RFP sequence falls right before the 
shRNA sequence. 
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These 4 pcDNA-FLEX-shRNA-MKP3 clones were then studied in HEK293 cells to 
determine their ability to silence MKP3 expression in vitro. The HEK293 cell 
concentration used in these studies was first optimized using various different cell 
concentrations to achieve the best possible RFP and Myc-tagged MKP3 protein 
expression. A HEK293 cell concentration of 500,000 cells per well of a 12-well 
plate gave the best Myc-tagged MKP3 protein expression for the positive control 
sample (containing just Myc-MKP3 DNA and pcDNA). All of other cell 
concentrations did not give a good signal for Myc-tagged MKP3 protein 
expression. It was important to find a cell concentration that gave the best Myc-
tagged MKP3 signal since this expression for the positive control sample would be 
used to calculate MKP3 expression without any silencing by shRNA. A HEK293 
cell concentration of 500,000 cells also gave the best RFP expression for one of 
the pcDNA-FLEX-shRNA-MKP3 clone samples. Again, all other cell 
concentrations did not give a good signal for RFP expression, and it was important 
to find a cell concentration that gave the best RFP expression since this expression 
would indicate how well the shRNAs are being expressed. 
The transfection conditions used in these in vitro studies was also optimized using 
various different amounts of DNA transfected with different amounts of transfection 
reagent to achieve the best possible Myc-tagged MKP3 protein expression. These 
optimization experiments showed that 2 µg of DNA transfected with 4 µL of 
transfection reagent (a 1:2 ratio of DNA amount to transfection reagent amount) 
gave the best Myc-tagged MKP3 protein expression for the positive control sample 
containing only pcDNA and Myc-MKP3 DNA. All other transfection condition 
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combinations did not give a good Myc-tagged MKP3 protein expression. As just 
mentioned in the previous paragraph, it was important to determine the 
transfection conditions that gave the best Myc-tagged MKP3 protein expression 
since this expression would be used as a positive control without any MKP3 
silencing to compare to the shRNA samples in order to determine how much 
silencing the shRNAs induced. Together, these optimized transfection conditions 
as well as the optimized HEK293 cell concentration were used to study MKP3 
silencing by the 4 pcDNA-FLEX-shRNA-MKP3 clones. 
In vitro studies of the 4 pcDNA-FLEX-shRNA-MKP3 clones showed that not all of 
the shRNAs were successful in silencing MKP3 protein expression. In fact, none 
of the 4 pcDNA-FLEX-shRNA-MKP3 clones were able to completely silence MKP3 
protein expression, and pcDNA-FLEX-shRNA-MKP3-3-1373 barely decreased 
MKP3 protein expression from its expression in the positive control sample. 
pcDNA-FLEX-shRNA-MKP3-2-1096 did knockdown MKP3 protein expression to a 
certain extent, however, the amount of knockdown was not considered statistically 
significant by one-way ANOVA statistical analysis with a Dunnett post hoc test. 
pcDNA-FLEX-shRNA-MKP3-4-1337 did induce a significant reduction (*p<0.05) of 
MKP3 protein expression when compared to the positive control sample, however 
it was not as effective in silencing MKP3 protein expression as pcDNA-FLEX-
shRNA-MKP3-1-1254, which significantly reduced (***p<0.001) MKP3 protein 
expression by about 50% when compared to the positive control.  
RFP expression indicates that the shRNA in the pcDNA-FLEX-shRNA-MKP3 
clone is being successfully expressed since the RFP sequence falls right before 
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the shRNA construct. Therefore, no RFP expression for a pcDNA-FLEX-shRNA-
MKP3 clone sample would mean that the shRNA in the clone is not being 
expressed, and that any observed silencing of MKP3 protein expression cannot be 
attributed to the shRNA itself. However, the amount of RFP expression does not 
directly correlate with the effectiveness of an shRNA, though it may perhaps 
indicate how much shRNA is being expressed in that sample. 
The RFP expression of the pcDNA-FLEX-shRNA-MKP3 clone samples showed 
that this expression was varied amongst the 4 pcDNA-FLEX-shRNA-MKP3 clones. 
pcDNA-FLEX-shRNA-MKP3-1-1254 and pcDNA-FLEX-shRNA-MKP3-4-1337 
both induced significant silencing of MKP3 protein expression, however pcDNA-
FLEX-shRNA-MKP3-1-1254 had a much higher RFP expression than pcDNA-
FLEX-shRNA-MKP3-4-1337. pcDNA-FLEX-shRNA-MKP3-3-1373 barely 
decreased any MKP3 protein expression, however this sample had the same 
amount of RFP expression as the sample with the most effective silencing of MKP3 
(pcDNA-FLEX-shRNA-MKP3-1-1254). Thus no clear conclusion can be drawn 
from the RFP expression of the pcDNA-FLEX-shRNA-MKP3 clones. 
In vitro studies of the pcDNA-FLEX-shRNA-MKP3 clones in the presence or 
absence of Cre recombinase showed that MKP3 silencing is Cre dependent. The 
pcDNA-FLEX-shRNA-MKP3 clone samples that did not contain Cre essentially 
further verified the MKP3 silencing results seen from the previous set of 
experiments, where both pcDNA-FLEX-shRNA-MKP3-1-1254 (***p<0.001) and 
pcDNA-FLEX-shRNA-MKP3-4-1337 (**p<0.01) induced significant reduction of 
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MKP3 protein expression, pcDNA-FLEX-shRNA-MKP3-1-1254 being the most 
effective at silencing MKP3 protein expression. 
However, in the pcDNA-FLEX-shRNA-MKP3 clone samples that contained Cre, 
the MKP3 silencing effects were eliminated and the reverse effects were observed, 
though significance in these reversal effects were only found for pcDNA-FLEX-
shRNA-MKP3-1-1254 (**p<0.01) and pcDNA-FLEX-shRNA-MKP3-4-1337 
(*p<0.05). This occurred because the shRNAs in the pcDNA-FLEX-shRNA-MKP3 
clones were designed in the forward orientation where they would be expressed 
without Cre, and the presence of Cre reverses the orientation of the shRNAs, 
causing them to no longer be expressed and therefore not being able to silence 
MKP3 protein expression. Thus the MKP3 protein expression of the pcDNA-FLEX-
shRNA-MKP3 clone samples with Cre was very similar to the MKP3 protein 
expression of the positive control sample that did not contain any pcDNA-FLEX-
shRNA-MKP3 clones. 
RFP expression of the pcDNA-FLEX-shRNA-MKP3 clone samples with or without 
Cre also showed the Cre dependence of RFP expression. Ideally, it was expected 
that Cre would eliminate RFP expression since Cre would suppress shRNA 
expression. However, pcDNA-FLEX-shRNA-MKP3 clone samples that contained 
Cre showed only reduced levels of RFP expression (rather than elimination of RFP 
expression) compared to the pcDNA-FLEX-shRNA-MKP3 clone samples that did 
not contain Cre, though this reduction in RFP expression was found to be 
insignificant by statistical analysis. This implies that since RFP expression was 
present but slightly reduced after the addition of Cre, shRNA expression was only 
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slightly reduced in these samples and Cre was not able to fully suppress shRNA 
expression. As discussed before, Cre reverses the orientation of the forward 
direction shRNAs, which decreases the amount of shRNAs being expressed in the 
samples, which can be correlated to the reduction of RFP expression seen in the 
pcDNA-FLEX-shRNA-MKP3 clone samples that contain Cre. 
It is important to note that pcDNA-FLEX-shRNA-MKP3 clone samples containing 
reverse direction shRNA should also be studied in vitro in the presence and 
absence of Cre, since the most effective shRNA will eventually be engineered in 
the reverse direction for in vivo studies so that it will only be expressed and induce 
MKP3 silencing in dopaminergic cells that contain Cre. In such an experiment, the 
absence of Cre in pcDNA-FLEX-shRNA-MKP3 clone samples containing the 
reverse direction shRNA should not show any MKP3 silencing or RFP expression. 
However, the presence of Cre in such samples will flip the orientation of the reverse 
direction shRNAs, causing them to be expressed, and therefore both MKP3 
silencing and RFP expression is expected in such pcDNA-FLEX-shRNA-MKP3 
clone samples containing Cre. 
Therefore, these in vitro studies preliminarily conclude that the pcDNA-FLEX-
shRNA-MKP3-1-1254 clone contains the most effective shRNA to silence MKP3 
expression amongst all of the 4 shRNAs being tested in this study. This shRNA 
will most likely be selected to proceed with further cloning of the shRNA into an 
AAV vector to study the effects of MKP3 silencing in vivo and its implications in 
cocaine addiction. However, it is important to note that this shRNA is only partially 
effective at silencing MKP3 protein expression, and that it may be beneficial to 
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design an even more effective shRNA to target the MKP3 gene and better silence 
its expression, prior to moving on to in vivo studies with pcDNA-FLEX-shRNA-
MKP3-1-1254. In order to best understand MKP3’s role in cocaine addiction, there 
needs to be as much MKP3 silencing as possible so that the behavioral effects 
observed can be fully attributed to the absence of MKP3 protein expression. 
Perhaps the same set of in vitro experiments should be conducted with the 
additional step of measuring transfection efficiency in all experimental samples 
with a method known as fluorescence in situ hybridization (23). This would perhaps 
lead to better results since only the HEK293 cells that were properly transfected 
with the desired DNAs would be analyzed, and any cells that did not get properly 
transfected would be excluded from analysis. For example, in the sample that 
contained Myc-MKP3 DNA, shRNA, and Cre, if any of those DNAs did not get 
properly transfected into all cells then Cre’s effect on MKP3 silencing could not be 
properly assessed, which may have occurred in the in vitro experiments of this 
study. Measuring the transfection efficiency of all samples in future in vitro 
experiments of this project will avoid this discrepancy from occurring.  
There are other methods to silence gene expression, some of which are still being 
developed by other researchers. Newer methods of gene silencing currently being 
further developed include genome editing techniques such as transcription 
activator-like effector nucleases (TALEN) (24) and clustered regularly interspaced 
palindromic repeat (CRISPR) associated Cas9 proteins (25). Since these 
techniques affect the genetic code by inducing a double-stranded break in the 
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gene of interest, they are permanent mechanisms of gene silencing where there 
is complete knockout or elimination of gene function (26).  
In this project, complete knockout of gene function is not desired since MKP3 is a 
key regulator in the widespread ERK1/2 signaling pathway, and elimination of 
MKP3 function would severely impact the development and normal functioning of 
the animals used in future studies of this project (27). Additionally, the 
CRISPR/Cas9 system could not be used to silence MKP3 expression due to size 
limitations, since this system only allows for a 20 nucleotide RNA sequence to 
target the gene of interest, which is too short of a sequence size to target the MKP3 
gene (28). Therefore, traditional knockdown methods of silencing gene expression 
are often preferred over knockout methods of gene silencing, especially for the 
overall long-term aim for this specific project (29).  
A widely used traditional method of gene expression silencing is using shRNA to 
knockdown gene expression through the RNAi pathway, which was the strategy 
utilized in this project. Knockdown of gene expression can also be achieved with 
siRNA, which also utilizes the RNAi pathway (30). The knockdown effects of 
shRNA are typically more potent and much more long lasting that siRNA (18), and 
lead to less off-target silencing effects than siRNA (19). Additionally, shRNA can 
be incorporated into the genome and gene expression silencing can be achieved 
at specific times through the use of an inducible promoter (31). 
It is important to note that both of these strategies do not completely eliminate the 
gene of interest but rather temporarily reduce gene expression levels by degrading 
the mRNA and protein products of this gene (30). Though this temporary amount 
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of gene expression silencing may not be enough for some molecular areas of 
interest, this knockdown method has advantages over knockout methods 
depending upon how much gene expression silencing is desired for a specific 
project. Knockdown methods do not permanently alter the genotype of the animal, 
which is why it is the preferred approach for this project since only transient levels 
of MKP3 silencing is desired for this project rather than completely eliminating 
MKP3 expression. The uniqueness of the RNAi-based genetic tool being 
developed in this project is the additional cell specificity that can be achieved with 
the use of Cre recombinase. 
Future in vivo studies will utilize the specificity of this Cre recombinase-based 
genetic tool to only silence MKP3 protein expression in dopaminergic cells, since 
the transgenic animals that will be used will be engineered to only express Cre 
recombinase in TH containing cells (dopaminergic neurons). The AAV vector 
containing the most effective shRNA will be directly injected into the VTA to induce 
MKP3 silencing in dopaminergic neurons. Behavioral assays will be performed in 
cocaine-treated rats with the AAV vector to determine how MKP3 silencing affects 
the formation of addictive behavior, with the hope of ultimately understanding 
MKP3’s role in cocaine addiction.  
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